Cingulate

Cingulate EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Cingulate (CING) as of Nov 4, 2026 is -3.79. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -4.80 — a change of -20.92% (higher).

EV/EBITDA

-3.79

YoY

-20.92%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Cingulate is 2025 -3.79 . EV/EBITDA (Enterprise Value to EBITDA) of Cingulate was 2024 -4.80 . It decreases by -20.92% higher compared to the previous year.

The Cingulate EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
-7.20 USD
Jan 1, 2020
-11.72 USD
Jan 1, 2021
-3.23 USD
Jan 1, 2022
-4.72 USD
Jan 1, 2023
-3.76 USD
Jan 1, 2024
-4.80 USD
Jan 1, 2025
-3.79 USD
The Cingulate EV/EBITDA history
YEAREV/EBITDAYoY
-3.79-20.92%
-4.80+27.55%
-3.76-20.38%
-4.72+46.14%
-3.23-72.42%
-11.72+62.85%
-7.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

EV/EBITDA (Enterprise Value to EBITDA) of Cingulate is -3.79 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Cingulate changed from -4.80 to -3.79, representing a -20.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Cingulate since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Cingulate with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cingulate

All Key Metrics — Cingulate